ClinicalTrials.gg
CompletedNCT05957107Updated Jul 9, 2025

Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis

A Phase 2 interventional study of Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection in Rheumatoid Arthritis, sponsored by Beijing VDJBio Co., LTD.. Completed at 15 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Beijing VDJBio Co., LTD. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled May 2022, registered Jul 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
34th of 110
181 · median 97
Started
2022
the only one that year
Phase 2
5 of 110
1 open now
Registered
107th of 110
by date
Lead sponsor
1 of 110
Beijing VDJBio Co., LTD.

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 34th largest by enrollment, is the only one that started in 2022, is one of 5 in phase 2, and was the 107th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo and tocilizumab controlled phase II trial in RA patients to evaluate the initial efficacy, safety, pharmacokinetic, pharmacodynamic characteristics, and immunogenicity of VDJ001 in RA patients.

Read the detailed description

After screening, eligible subjects were randomly assigned in a 1:1:1:1 ratio to VDJ001 4 mg/kg group, VDJ001 6 mg/kg group, placebo group, and tocilizumab group to receive trial drug or control drug every 4 weeks. The treatment course was 12 weeks (D1, W4, W8 administration, followed up to W12).

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must meet all of the following criteria to be included:

    1. Voluntarily sign the ;
    2. Age 18-75 years old (including boundary values);
    3. RA was diagnosed according to the 1987 American College of Rheumatology (ACR) criteria or the 2010 ACR and EULAR classification criteria;
    4. Moderate to severe active RA was determined according to the following criteria: the number of joint swelling ≥6 (based on 66 joints) and the number of joint tenderness ≥6 (based on 68 joints), and the C-reactive protein (CRP) ≥10 mg/L or erythrocyte sedimentation rate (ESR) ≥28 mm/h;
    5. Had received oral methotrexate (MTX) therapy for at least 12 weeks with a stable dose (MTX dose of 7.5-25 mg/ week) for at least 4 weeks before randomization; Subjects with a history of parenteral MTX use (subcutaneous, intramuscular, or intravenous) were eligible, but they had to have received a stable dose of MTX 7.5 to 25mg/ week orally for ≥4 weeks before randomization;
    6. If subjects were taking prednisone or equivalent at the time of screening, they were treated with a stable dose (prednisone dose ≤10mg/ day) for at least 4 weeks before randomization.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following conditions will not be included in the study:

<!-- -->

  1. Weight >100 kg or \<40 kg.
  2. Patients with ACR function grade IV or long-term bedridden/wheelchair-bound.
  3. Persons with allergies or known allergies to any of the ingredients and/or other similar products under study.
  4. The investigator determined that the subject had undergone or planned surgery that might affect the study evaluation of the evaluated joint.
  5. Patients with rheumatic immune diseases other than rheumatoid arthritis, uncontrolled immune system diseases requiring oral treatment, were considered by the investigators to influence trial evaluators.
  6. Primary or secondary immunodeficiency (previous or current active).
  7. Previous or current cancer.
  8. A history of any lymphoproliferative disease, such as EBV-associated lymphoproliferative disease, lymphoma, leukemia, myeloproliferative disease, multiple myeloma, or signs and symptoms suggestive of current lymphoproliferative disease.
  9. The presence of serious, poorly controlled concomitant diseases, such as (but not limited to) neurological, cardiovascular, hepatic, renal, gastrointestinal, and endocrine diseases, which in the judgment of the investigator may prevent the subjects from participating in the study.
  10. Have any congenital or acquired neurological disease, vascular disease, or systemic disease, especially joint pain and swelling (e.g., Parkinson's disease, cerebral palsy, diabetic neuropathy) that may affect the evaluation of the effectiveness of this study.
  11. The following infections are known: Recurrent active bacteria, viruses, fungi, mycobacteria infection or other (including but not limited to, and atypical mycobacteria tuberculosis disease, chest X-ray examination showed granulomatous disease, virus (HCV) infection, infection, herpes zoster, but does not include the nail bed fungus infection), or 6 months before the filter has a history of chronic infection, Or any major episode of infection requiring hospitalization or intravenous antibiotic treatment within 4 weeks prior to screening or oral antibiotic treatment within 2 weeks prior to screening, or a history of tuberculosis; For those who screened positive for TB, enrollment was determined by the investigator after prophylactic treatment.
  12. Subjects who received live/attenuated/inactivated COVID-19 vaccine within 4 weeks prior to the screening visit or were known to receive live/attenuated/inactivated COVID-19 vaccine during the 12-week treatment observation period.
  13. Patients who had used lymphocyte depletion agents/therapies, alkylating agents, total lymphoid irradiation, or other therapies before screening or planned to use them during the study.
  14. Previous treatment with IL-6 and IL-6R inhibitors.
  15. Use biological DMARDs at the following times:

    A) Anapheresis, etanercept: within 28 days before administration;

    B) Adalimumab, infliximab: within 56 days before administration;

    C) Golimumab and cetuzumab: within 70 days before administration;

    D) Abacept: within 84 days before administration;

    E) Denoxemide: within 150 days before administration;

    F) Rituximab: within 180 days before administration.

  16. Abiotic DMARDs other than MTX were administered within 28 days prior to dosing (subjects without chloroquine, hydroxychloroquine, leflunomide within 56 days prior to dosing, or no more than 28 days after standard koleenamine treatment or active carbon washout were not eligible).
  17. Had received intra-articular or extra-intestinal corticosteroid therapy within 28 days prior to dosing.
  18. Who had been immunized with genofin, gold thiodextrose (gold for injection), gold thiomalate (gold for injection), or oral polio vaccine within 56 days prior to administration.
  19. Patients who received intravenous immunoglobulin, plasma exchange or Prosorba column within 24 weeks before screening.
  20. Participated in clinical studies of other drugs within 1 month prior to screening or within 5 half-lives of other experimental drugs, whichever is longer.
  21. surface antigen (HBsAg) positive, or if hepatitis B core antibody (HBcAb) positive, HBV DNA test is added and HBV DNA> the lower limit of detection.
  22. The laboratory test value (retest is allowed, and the last test result shall prevail) meets any of the following conditions:

    • Serum creatinine: female subjects had serum creatinine >1.4 mg per deciliter (124 μmol per liter); Serum creatinine > 1.6 mg/dL (141 μmol/L) in male subjects;

    or AST> 1.5 times the (ULN);

    • count \<80×109/ L;
    • the WBC \< 3.5 x 109 / L;
    • Total > 1.5 times ULN.
  23. Female subjects who had a positive pregnancy test during pregnancy, or breastfeeding, or screening, or who were unable to use effective from the screening period until 6 months after completion or termination of the trial (including male subjects and their female spouses).
  24. Other ineligible subjects were judged by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
181 participants (actual)

Study arms

  • Experimental
    Injection of recombinant humanized monoclonal antibody against interleukin-6 receptor 4 mg/kg

    Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4 mg/kg as the low dose group.

    Biological: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection

  • Experimental
    Injection of recombinant humanized monoclonal antibody against interleukin-6 receptor6mg/kg

    Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 6mg/kg as the middle dose group.

    Biological: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection

  • Experimental
    placebo control

    placebo control

    Biological: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection

  • Experimental
    Tocilizumab Injection8mg/kg

    Tocilizumab Injection8mg/kg

    Biological: Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of patients who achieved ACR20 at week 12.

    Proportion of patients who achieved American College of Rheumatology 20% improvement criteria (ACR20) at week 12.

    Time frame: 12 weeks

Secondary outcomes

  1. Proportion of patients who achieved ACR50, ACR70 at week 12.

    Proportion of patients who achieved American College of Rheumatology 50%, 70% improvement criteria at week 12.

    Time frame: 12 weeks

  2. Proportion of patients who achieved DAS28-CRP <2.6, DAS28-ESR <2.6, DAS28-CRP <3.2, DAS28-ESR <3.2 at week 12.

    DAS28-CRP=0.56\*(TJC28)1/2+0.28\*(SJC28)1/2+0.014\*GH+0.36\*ln(CRP+1)+0.96; DAS28-ESR=0.56\*(TJC28)1/2+0.28\*(SJC28)1/2+0.014\*GH+0.70\*ln(ESR); In the formula, TJC28 = joint count of pressure and pain at 28 joints, SJC28 = joint count of swelling at 28 joints, GH = general health status, i.e., patient's overall assessment of disease activity, ln = natural logarithm.

    Time frame: 12 weeks

  3. Proportion of patients who achieved a good response rate on the Clinical Disease Activity Index (CDAI) (defined as ≥50% improvement in CDAI or CDAI ≤2.8) at Week 12.

    CDAI=TJC28+SJC28+PGA+PhGA In the formula, TJC28 = joint counts of pressure and pain at 28 joints, SJC28 = joint counts of swelling at 28 joints,PhGA stands for physician's global visual analogue scale of disease activity in cm, and PtGA stands for patient's global visual analogue scale of disease activity in cm.

    Time frame: 12 weeks

  4. Change in duration of morning stiffness at week 12 relative to baseline and rate of change.

    Morning stiffness refers to the phenomenon that the diseased joints are stiff for a longer period of time in the morning after standing still, such as the feeling of glue, which is gradually reduced after appropriate activities.

    Time frame: 12 weeks

  5. Patient ratings of arthralgia

    Change in patient rating of arthralgia (PtAAP) at week 12 relative to baseline and rate of change.

    Time frame: 12 weeks

  6. Patient's overall assessment of the condition

    Patient's overall assessment of the condition (PtGA) at week 12 change from baseline and rate of change.

    Time frame: 12 weeks

  7. Physician's Global Assessment of Condition

    Change in Physician's Global Assessment of Condition (PhGA) relative to Baseline and Rate of Change at Week 12.

    Time frame: 12 weeks

  8. Patient Health Assessment Questionnaire

    Change in Patient Health Assessment Questionnaire (HAQ-DI) Score Relative to Baseline and Rate of Change at Week 12.

    Time frame: 12 weeks

  9. Health Status Questionnaire (SF-36)

    Change from baseline in Week 12 Health Status Questionnaire (SF-36) scores and rate of change.

    Time frame: 12 weeks

  10. Functional Assessment of Chronic Illness Therapy-Fatigue Scale

    Change from baseline and rate of change in Functional Assessment of Chronic Illness Therapy-Fatigue Scale (FACIT-F) score at week 12.

    Time frame: 12 weeks

07

Study locations

15 sites
  • Peking University People's Hospital
    Beijing, Beijing Municipality 010000, China
  • Baoji Central Hospital
    Baoji, China
  • Beijing Hospital
    Beijing, China
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, China
  • Chenzhou First People's Hospital
    Chenzhou, China
  • Pingxiang People's Hospital
    Jiangxi, China
  • Jilin Province People's Hospital
    Jilin City, China
  • Affiliated Hospital of North Sichuan Medical College
    Nanchong, China
  • Drum Tower Hospital Affiliated to Nanjing University Medical School
    Nanjing, China
  • Puyang Oilfield General Hospital
    Pujiang, China
  • Qilu Hospital of Shandong University
    Shandong, China
  • Peking University Shenzhen Hospital
    Shenzhen, China
  • People's Hospital of Xinjiang Uygur Autonomous Region
    Xinjiang, China
  • Zaozhuang Municipal Hospital
    Zaozhuang, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Jun 2023, 12 months.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 12 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2023
First posted
Jul 24, 2023
StartActual
May 26, 2022
Primary completionActual
Jun 2, 2023
CompletionActual
Jun 2, 2023
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05957107
Lead sponsor
Beijing VDJBio Co., LTD.
Responsible party
Sponsor
First posted
Jul 24, 2023
Start date
May 26, 2022
Primary completion
Jun 2, 2023
Completion
Jun 2, 2023
Last update
Jul 9, 2025

Study contacts

Zhan-guo Li
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion